WJPPS Citation

Login

Search

News & Updation

  • Updated Version
  • WJPPS introducing updated version of OSTS (online submission and tracking system), which have dedicated control panel for both author and reviewer. Using this control panel author can submit manuscript
  • Call for Paper
    • WJPPS  Invited to submit your valuable manuscripts for Coming Issue.
  • Journal web site support Internet Explorer, Google Chrome, Mozilla Firefox, Opera, Saffari for easy download of article without any trouble.
  •  
  • New Impact Factor
  • WJPPS Impact Factor has been Increased to 8.025 for Year 2024.

  • WJPPS: MARCH ISSUE PUBLISHED
  • March Issue has been successfully launched on 1 March 2024.

  • ICV
  • WJPPS Rank with Index Copernicus Value 84.65 due to high reputation at International Level

  • Scope Indexed
  • WJPPS is indexed in Scope Database based on the recommendation of the Content Selection Committee (CSC).

Abstract

RECENT ADVANCES ON THE EFFECTIVENESS OF METFORMIN THERAPY IN DIABETIC PATIENTS

Swaminathan Selvanayagam*, Arun Kumar Daniel, Dhananjayan Rangan and Sridevi Anantharaman

ABSTRACT

Metformin is the first line choice of oral antidiabetic drug to control blood glucose levels in Type 2 Diabetes Mellitus (T2DM) patients. It is marketed under the trade name Glucophage. It is found to be very effective for the treatment of T2DM in obese people with normal kidney function. It increases body’s response to insulin. It contains the ingredient metformin hydrochloride and it is available both in combination with other drugs or as single as metformin. Glutamate Decarboxylase or Glutamic acid Decarboxylase (GAD) is an enzyme that catalyses the decarboxylation of glutamate to -Amino Butyric Acid (GABA) and CO2. In mammals, GAD exists in two isoforms, GAD 67 and GAD 65 according to molecular weights of 67 and 65 K respectively and they are targets of autoantibodies in people who develop Type 1 Diabetes Mellitus (T1DM) or Latent Autoimmune Diabetes of Adulthood (LADA). GAD is one of the strongest candidate autoantigen involved in triggering beta-cell-specific autoantibody and GAD-Antibody (GADA) is one of the most commonly detected antibodies in newly diagnosed T1DM. This review article brings out the outcome of recent research findings on the use of metformin, its merits and demerits in controlling both types of DM and the laboratory diagnostic link of GADA to metformin therapy.

Keywords: Metformin, GAD, T2DM, LADA, GADA.


[Download Article]     [Download Certifiate]

Call for Paper

World Journal of Pharmacy and Pharmaceutical Sciences (WJPPS)
Read More

Online Submission

World Journal of Pharmacy and Pharmaceutical Sciences (WJPPS)
Read More

Email & SMS Alert

World Journal of Pharmacy and Pharmaceutical Sciences (WJPPS)
Read More